Dr. Reddy’s Lab sells Jeedimetla API manufacturing business unit to Therapiva
Dr. Reddy’s Laboratories has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla in Hyderabad, to Therapiva an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and its employees. Therapiva is a joint venture between Omnicare Drugs India (100% subsidiary of Neopharma LLC, Abu Dhabi) and Laxai Life Sciences.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.